Subscribe To
Fairfax financial: q3 2023 results indicate banner year ahead
YTD book value per share increased 16.4% before dividends and 15% ex-dividends. YTD gross premiums written up 7.5% with a combined ratio of ~94%. Mana...
November 4, 2023, 12:42 am
Weekly economic & financial commentary: q4 appears off to a slower start
Summary United states: Q4 Appears Off to a Slower start ...
November 4, 2023, 12:38 am
The weekly bottom line: the fed’s door is still open
U.S. Highlights The Federal Reserve’s policy statement took center ...
November 4, 2023, 12:36 am
Canadian imports softening on lower consumer and business spending
The week ahead will be a lighter one for data releases after signs of decelerating Canadian GDP growth, a higher unemployment rate in both the U.S. an...
November 4, 2023, 12:31 am
Rosen, a leading law firm, encourages pacwest bancorp investors with losses in excess of $100k to secure counsel before important deadline in securities class action – pacw, pacwp
NEW YORK, Nov. 03, 2023 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, re...
November 4, 2023, 12:30 am
Closing bell: ci gold bullion fund etf hg cad flat on wednesday (valt)
Today, CI Gold Bullion Fund ETF Hg CAD shares closed at $24.75 after opening the day at $24.75. It traded at a low of $24.75 to a high of $24.75. The ...
November 4, 2023, 12:29 am
Investors sue barclays for inaccurately disclosing ex-ceo’s ties to jeffrey epstein – hagens berman
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Barclays PLC (BCS) Investors with Sub...
November 4, 2023, 12:22 am
U.s. ipo weekly recap: biotech lexeo stumbles after $100 million ipo
Two IPOs are currently scheduled for the week ahead, although some small issuers may join the calendar late. As of 11/2/2023, the Renaissance IPO Inde...
November 4, 2023, 12:21 am
Otlk investor alert: robbins geller rudman & dowd llp announces that outlook therapeutics, inc. investors with substantial losses have opportunity to lead the outlook therapeutics class action lawsuit
SAN DIEGO, Nov. 03, 2023 (GLOBE NEWSWIRE) — Robbins Geller Rudman & Dowd LLP announces that the Outlook Therapeutics class action lawsuit seeks to r...
November 4, 2023, 12:13 am
Canon isn't picture-perfect
Canon has operational advantages in its printing segment and has a strong global presence in various ma...
November 4, 2023, 12:12 am
Seacor marine: good company, but not good enough
The OSV market is expected to face a deficit due to low order book levels and declining shipyard capacity, but growing demand from deep-water protects...
November 4, 2023, 12:05 am
South korea's exports rebound in october 2023
South Korea's exports to mainland China have remained weak during 2023, recording a decline of 9.5% y/y in October. According to late...
November 4, 2023, 12:04 am
Summary 11/6 – 11/10
Monday, Nov 6, 2023 Tuesday, Nov 7, 2023 Wednesday, Nov 8, 2023 Thursday, Nov 9, 2023 Friday, Nov 10, 2023 The po...
November 4, 2023, 12:00 am
Rosen, top ranked investor counsel, encourages tandem diabetes care, inc. investors to secure counsel before important deadline in securities class action – tndm
NEW YORK, Nov. 03, 2023 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, re...
November 4, 2023, 12:00 am
Regal rexnord corporation (rrx) q3 2023 earnings call transcript
Regal Rexnord Corporation (NYSE:RRX ) Q3 2023 Earnings Conference Call November 2, 2023 10:00 AM ET Company Participants Robert Barry – Vice Preside...
November 3, 2023, 11:54 pm
Closing bell: rbc us banks yield cad hgd index etf up on thursday (rubh)
In today’s trading, RBC US Banks Yield CAD Hgd Index ETF shares closed at $12.35 after opening the day at $12.27. Intraday prices ranged from $12.27...
November 3, 2023, 11:44 pm
Egain corporation (egan) q1 2024 earnings call transcript
eGain Corporation (NASDAQ:EGAN ) Q1 2024 Earnings Conference Call November 2, 2023 5:00 PM ET Company Participants Jim Byers - MKR IR Ashu Roy - CEO E...
November 3, 2023, 11:30 pm
Replimune presents updated interim results from the artacus clinical trial of rp1 monotherapy in solid organ and hematopoietic cell transplant recipients with skin cancers during oral presentation at
RP1 as monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent in evaluable patients WOBURN, Mass., Nov. 03, 2...
November 3, 2023, 11:30 pm
Replimune presents updated interim results from the artacus clinical trial of rp1 monotherapy in solid organ and hematopoietic cell transplant recipients with skin cancers during oral presentation at
RP1 as monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent in evaluable patients WOBURN, Mass., Nov. 03, 2...
November 3, 2023, 11:30 pm
Replimune presents updated interim results from the artacus clinical trial of rp1 monotherapy in solid organ and hematopoietic cell transplant recipients with skin cancers during oral presentation at
RP1 as monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent in evaluable patients WOBURN, Mass., Nov. 03, 2...
November 3, 2023, 11:30 pm